ER1234 .pdf

File information


Original filename: ER1234.pdf
Author: Natalya

This PDF 1.5 document has been generated by Microsoft® Word 2016, and has been sent on pdf-archive.com on 11/06/2019 at 07:15, from IP address 92.253.x.x. The current document download page has been viewed 165 times.
File size: 447 KB (1 page).
Privacy: public file


Download original PDF file


ER1234.pdf (PDF, 447 KB)


Share on social networks



Link to this file download page



Document preview


2ND
r

INTERNATIONAL

NTNU SYMPOS UM
5

CURRENT AND FUTURE
CLINICAL BIOMARKERS OF CANCER

NTE

i

RNR

T

I

ON

H

NTNU

L

SYMPOSIUMON
i
i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

i

C L(N I Cfi L B l0M RRKERSO FCANCER

From diagnosis to immunotherapy - why is precision medicine so difficult?

THURSDAY-FRIDAY
JUNE 14-15
(08:00-17:30)

f
PROGRAM

DAY ONE - UTH JUNE
IMM UNO THE RAP Y IN CAN CE R

DAY TWO - 1 5TH JUNE
BI OMA RKE RS I N P RE CIS ION DI A GNOSIS AND TRE A TMEN T

- A REAL BREAKTHROUGH - BUT FOR THE FEW? 07.00 • 12.00

REGISTRATI0N/P0STER HANGING

WEL CO ME
8.008.508.100LWEUS

- NOVEL DEVELOPMENTS

08.008.05 CULTURAL AWAKENING
08.508.10 WELCOME
CHAIRS: FRED HIRSCH, KLAAS MAX, SHOUYU WANG, SOFIA AGELAKI

8.05 CULTURAL EVENT
08.10 PAL R0MUNDSTAD, DEAN OF RESEARCH, MEDICAL FACULTY, NTNU, NORWAY
08.15 OLUF DIMITRI R0E, SYMPOSIUM CHAIRMAN CHAIRS: MADHAV V. D0DAPHKAR, JOHANNA

KEYN OTE

08.1008.40 LUNG CANCER- FROM BEST SUPPORTIVE CARE TO IMMUNOTHERAPY. THE BIOMARKERS TALE/ FRED
HIRSCH, UNIVERSITY OF COLORADO, AURORA, USA

KEYN OTE

F ROM M icro RNA AN D ME TA BO LI TES TO CE LLS , W HA T BI OMA RK ERS TO CHOO SE?

T- CEL L AN D O THE R IM MU NO THERAP IES IN CAN CE R -

8.40- 9.00 HUMAN PLASMA AND SERUM EXTRACELLULAR SMALL RNA REFERENCE PROFILES AND THEIR CLINICAL UTILITY/ KLAAS
MAX, (THOMAS TUSCHL LAB) ROCKEFELLER UNIVERSITY, NY, USA
9.09.20 LONG NON-CODING RNA ROLE IN BREAST CANCER IN BONE AND BRAIN METASTASIS/ SHOUYU WANG, NANJING
MEDICAL UNIVERSITY, NANJING, CHINA
9.20- 9.40 CIRCULATING TUMOR CELLS AND MicroRNAS IN BREAST CANCER PATIENTS/ SOFIA AGELAKI, UNIVERSITY OF CRETE,
HERAKLION, GREECE

8.15-8.45 NATURAL KILLER T CELLS IN CANCER IMMUNOTHERAPY - RECENT PROGRESS AND CHALLENGES/ MADHAV V. DODAPHKAR,
EMORY UNIVERSITY SCHOOL OF MEDICINE, ATLANTA, USA
FUTURE PROSPECTIVE
8.45- 9.05 PENDING FAST CARS FOR CANCER
9.59.25 TCR-BASED CANCER IMMUNOTHERAPY - HOW CAN WE MOVE FORWARD/ JOHANNA OLWEUS, OSLO UNIVERSITY
HOSPITAL, OSLO, NORWAY
9.25-9.45 CANCER IMMUNOTHERAPY USING A NOVEL NANOPARTICLE MRNA DELIVERY PLATFORM/ OLE AUDUN WERNER HAABETH
(RONALD LEVY GROUP) STANFORD UNIVERSITY, STANFORD, USA
9.45-

10.00 COFFEE BREAK - POSTER EXHIBITION

IMM UNE CHE CK -PO IN T THE RAP Y

- IT WORKS WHEN IT WORKS, BUT WHY ARE SO MANY RESISTANT? CHAIRS:
ROBERT ANDERS, ANDREW MELLOR, CONRAD REUBER
10.010.30 PATHOLOGY S ROLE IN THE DEVELOPMENT OF IMMUNE THERAPY CLINICAL TRIALS/ ROBERT ANDERS (SUSAN
TOPALIAN GROUP) JOHNS HOPKINS, BALTIMORE, USA
10.30- 11.00 OVERCOMING IMMUNOTHERAPY RESISTANCE: IMMUNOTHERAPY, IDO AND TRYPTOPHAN, A NEW CONCEPT IN
CANCER TREATMENT/ ANDREW MELLOR, NEWCASTLE UNIVERSITY, UK

KEYN OTE II
11.0-

11.30 GUT MICROBIOME IN CONTROL OF CANCER IMMUNOTHERAPY/ CONRAD RAUBER, (LAURENCE ZITVOGELS GROUP)
INSTITUTE GUSTAVE ROUSSY, FRANCE
12.0-

CHAIRS: KAVITA DHODAPKAR, ASLAUG HELLAND, OLUF DIMITRI ROE

14.00 PENDING
14.20 B CELLS AND AUTOIMMUNITY FOLLOWING CHECKPOINT BLOCKADE THERAPY/ KAVITA DHODAPKAR EMORY

UNIVERSITY SCHOOL OF MEDICINE, ATLANTA, USA
14.2014.40 CLINICAL SIGNS OF IMMUNOTHERAPY TOXICITIES IN LUNG CANCER AND THEIR MANAGEMENT/ ASLAUG
HELLAND, OSLO UNIVERSITY HOSPITAL, OSLO, NORWAY
14.4015.00 THE COST OF NEW CANCER DRUGS, ETHICS AND HEALTH DISPARITIES/ OLUF DIMITRI ROE, LEVAN- GER
HOSPITAL/NTNU, NORWAY

15.015.30-

10.00 COFFEE BREAK- POSTER EXHIBITION

CHAIRS: ANA ROBLES, MAY-BRITT TESSEM, ALEX LESOKHIN, DUAN CHEN, HAINING YANG, HEDY KINDLER
10.010.20 LUNG CANCER BIOMARKERS: BEYOND GENOMICS/ ANA ROBLES (CURTIS HARRIS GROUP), NCI, WASHINGTON, USA
10.20- 10.40 EX VIVO METABOLIC FINGERPRINTING IDENTIFIES BIOMARKERS PREDICTIVE OF PROSTATE CANCER RECURRENCE
FOLLOWING RADICAL PROSTATECTOMY/ MAY-BRITT TESSEM, NTNU, NORWAY
10.40- 11.00 IMMUNOTHERAPY IN MYELOMATOSIS: THE PROMISE AND THE PROBLEMS/ ALEX LESOKHIN, MEMORIAL SLOAN
KETTERING CANCER CENTER, NEW YORK, USA
11.011.20 A NEW APPROACH FOR PANCREATIC CANCER BIOMARKER DISCOVERY USING PEPTIDOME/ DUAN CHEN, NTNU,
TRONDHEIM, NORWAY
11.20- 11.40 DISCOVERY OF HYPERACETYLATED HMGB1 AS A BLOOD DIAGNOSTIC IN MESOTHELIOMA/ HAINING YANG,
UNIVERSITY OF HAWAII, HONOLULU, USA
11.40- 12.00 MOLECULARLY STRATIFIED TREATMENT FOR MESOTHELIOMA/ HEDY KINDLER, UNIVERSITY OF CHICAGO, USA
12.0-

13.30 LUNCH/POSTER EXHIBITION. GOLD SPONSOR LECTURE

BI G D A TA IN BI OMA RKE R DIS CO VERY AN D P RE CISION ME DI CIN E

13.30 LUNCH/POSTER EXHIBITION. GOLD SPONSOR LECTURE

CL INI CAL P RO BL EMS IN I MM UN OTHERAP Y
13.3014.0-

9.40-

15.30 COFFEE BREAK- POSTER EXHIBITION
15.50 INFLAMMATION, MICROENVIRONMENT AND CANCER INVASIVENESS/ NADRA NILSEN, CEMIR, NTNU, TRONDHEIM,

CHAIRS: JEAN CLAUDE ZENKLUSEN, KRISTIAN HVEEM, NIKI KARACHALIOU, APOSTOLIA-MARIA TSIMBERIDOU
13.3014.00 OPEN ACCESS TO HUMAN GENE, PROTEOMICS AND METABOLOMICS DATA (TCGA); ESCALATING BIOMARKER
RESEARCH OR NOT?/ JEAN CLAUDE ZENKLUSEN (CONFIRMED), THE CANCER GENOME ATLAS, CENTER FOR CANCER GENOMICS, NCI,
NIH, WASHINGTON, USA
14.014.20 THE HUNT BIOBANK, A GOLD MINE FOR PROSPECTIVE BIOMARKER STUDIES/ KRISTIAN HVEEM, HUNT RESEARCH
CENTER, LEVANGER, NORWAY
14.20- 14.40 SWARM INTELLIGENCE-ENHANCED DETECTION OF NON-SMALL-CELL LUNG CANCER USING TUMOR-EDUCATED
PLATELETS/ NIKI KARACHALIOU, QUIRON DEXEUS UNIVERSITY HOSPITAL, BARCELONA, SPAIN
14.40- 15.00 INITIATIVE FOR MOLECULAR PROFILING AND ADVANCED CANCER THERAPY AND CHALLENGES IN THE
IMPLEMENTATION OF PRECISION MEDICINE/ APOSTOLIA-MARIA TSIMBERIDOU, MD ANDERSON, HOUSTON, USA
15.0-

15.30 COFFEE BREAK - POSTER EXHIBITION

NORWAY

ORAL P RESEN TA TIONS
15.30-

CL OSIN G KE YNO TE

ORAL P RESEN TA TIONS
16.016.1016.20-

16.30 TEN-MINUTE SESSIONS FOR SELECTED ORAL PRESENTATIONS

16.30-17.00 DISCOVERY OF THE FIRST "MAGIC BULLET" AND ITS TARGET: THE CML STORY/ ROBERT GALE, IMPERIAL COLLEGE,
LONDON, UK

16.10
16.20
16.30

CL OSIN G KE YNO TE
16.3017.00 PD1-DISCOVERY SAVES LIVES, BUT WHAT ABOUT THE RESISTANT CANCERS? RECENT PROGRESS AND
VISIONS/ KENJICHAMOTO, (TASUKU HONJO GROUP), KYOTO UNIVERSITY, JAPAN
17.017.30 CLOSING DISCUSSION AND SUMMARY
19.00 ONWARDS CONFERENCE DINNER WITH CULTURAL EVENTS (TICKETED EVENT, EXCEPT INVITED SPEAKERS)

Supported
GOL D SP ONSO R
Boehringer
Ingelheim

SILV E R S PONS O R
Bristol-Myers Squibb

BRON ZE SPO NSO RS

NBS

OTHER S U PPO RTERS
&

0NTNU

Ketssktf Iti n bttfre itiitn

AMGEN


Document preview ER1234.pdf - page 1/1


Related documents


er1234
cv2016 updated
2826pathology meetingprogram
96b8dd3355da3def61bdd2fe246f9d93
programme details and delegate profiles
er1235

Link to this page


Permanent link

Use the permanent link to the download page to share your document on Facebook, Twitter, LinkedIn, or directly with a contact by e-Mail, Messenger, Whatsapp, Line..

Short link

Use the short link to share your document on Twitter or by text message (SMS)

HTML Code

Copy the following HTML code to share your document on a Website or Blog

QR Code

QR Code link to PDF file ER1234.pdf